Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

NCT03700099 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Castration-resistant Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: Enzalutamide

Sponsor

Instituto do Cancer do Estado de São Paulo

Collaborators

[object Object]